Sistema de Salut de Catalunya
Institut Català de la Salut
[Molina I] PROSICS Barcelona. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Instituto René Rachou-FIOCRUZ Minas, 1715 Belo Horizonte, Brazil. [Marcolino MS] Department of Internal Medicine, Medical School and Telehealth Center, University Hospital, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Institute for Health Technology Assessment (IATS/ CNPq), Porto Alegre, Brazil. [Pires MC, Ramos LEF, Silva RT] Department of Statistics, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. [Guimarães-Júnior MH] Hospital Marcio Cunha, Ipatinga, Brazil
Vall d'Hebron Barcelona Hospital Campus
2022-05-02T13:12:52Z
2022-05-02T13:12:52Z
2021-10-13
Epidemiología; Microbiología; SARS-CoV-2
Epidemiologia; Microbiologia; SARS-CoV-2
Epidemiology; Microbiology; SARS-CoV-2
Chagas disease (CD) continues to be a major public health burden in Latina America. Information on the interplay between COVID-19 and CD is lacking. Our aim was to assess clinical characteristics and in-hospital outcomes of patients with CD and COVID-19, and to compare it to non-CD patients. Consecutive patients with confirmed COVID-19 were included from March to September 2020. Genetic matching for sex, age, hypertension, diabetes mellitus and hospital was performed in a 4:1 ratio. Of the 7018 patients who had confirmed COVID-19, 31 patients with CD and 124 matched controls were included (median age 72 (64–80) years-old, 44.5% were male). At baseline, heart failure (25.8% vs. 9.7%) and atrial fibrillation (29.0% vs. 5.6%) were more frequent in CD patients than in the controls (p < 0.05). C-reactive protein levels were lower in CD patients compared with the controls (55.5 [35.7, 85.0] vs. 94.3 [50.7, 167.5] mg/dL). In-hospital management, outcomes and complications were similar between the groups. In this large Brazilian COVID-19 Registry, CD patients had a higher prevalence of atrial fibrillation and chronic heart failure compared with non-CD controls, with no differences in-hospital outcomes. The lower C-reactive protein levels in CD patients require further investigation.
This study was supported in part by Minas Gerais State Agency for Research and Development (Fundação de Amparo à Pesquisa do Estado de Minas Gerais—FAPEMIG) [Grant Number APQ-00208-20], National Institute of Science and Technology for Health Technology Assessment (Instituto de Avaliação de Tecnologias em Saúde—IATS)/National Council for Scientific and Technological Development (Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq) [Grant Number 465518/2014-1], and CAPES Foundation (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) [Grant Number 88887.507149/2020-00].
Article
Published version
English
COVID-19 (Malaltia) - Complicacions; Chagas, Malaltia de - Complicacions; DISEASES::Parasitic Diseases::Protozoan Infections::Euglenozoa Infections::Trypanosomiasis::Chagas Disease; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; Other subheadings::Other subheadings::Other subheadings::/complications; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Mortality::Hospital Mortality; ENFERMEDADES::enfermedades parasitarias::infecciones por protozoos::infecciones por Euglenozoa::tripanosomiasis::enfermedad de Chagas; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::estadísticas vitales::mortalidad::mortalidad hospitalaria
Nature Research
Scientific Reports;11
https://doi.org/10.1038/s41598-021-96825-3
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3436]
